
Yale's Alessandro Santin, MD, emphasizes that "knowing our enemy" through sequencing is a way to identify targetable pathways for rare and aggressive ESS cases.

Alessandro Santin, MD, is a Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine

Yale's Alessandro Santin, MD, emphasizes that "knowing our enemy" through sequencing is a way to identify targetable pathways for rare and aggressive ESS cases.

Alessandro Santin, MD, highlights how POLE and mismatch repair mutations in high-grade ESS create a clinical opportunity for using immune checkpoint inhibitors.

"It's only when you acquire the type of deep knowledge in the molecular characteristic that you may really identify potential targets," said study investigator Alessandro Santin, MD.